Search

ADC for the Treatment of Breast Cancer

Author(s)

Runze Li

Affiliation(s)

University of California Davis, Davis, CA, 95616, America

Abstract

With environmental factors, personal factors and people's negligence of health issues, breast cancer has become a very serious problem for contemporary women. This has become one of the most common cancer diseases among women nowadays and has a very high mortality rate. In addition to traditional chemotherapy methods, antibody-drug conjugates (ADC) represent a novel therapeutic approach in the medical and pharmaceutical fields, especially in tumor treatment. ADC refers to the precise delivery of drugs to cancer cells using antibodies, which can address the side effects brought about by chemotherapy. Three ADC drugs will be mentioned in this article including Kadcyla, Enhertu and Trodelvy. This article will mainly discuss the mechanisms of three different types of ADC drugs, comparing the clinical manifestations in breast cancer and future development of ADC treatment for the breast cancer.

Keywords

Antibody-Drug Conjugates; Breast Cancer; HER2; Targeted Therapy

References

[1] Pondé, Noam, Philippe Aftimos, and Martine Piccart. "Antibody-drug conjugates in breast cancer: a comprehensive review." Current Treatment Options in Oncology 20 (2019): 1-22. [2] Marmé, Frederik. "Antibody-drug conjugates for breast cancer." Oncology Research and Treatment 45.1-2 (2022): 26-36. [3] Koster, Kira-Lee, Jens Huober, and Markus Joerger. "New antibody-drug conjugates (ADCs) in breast cancer—An overview of ADCs recently approved and in later stages of development." Exploration of Targeted Anti-tumor Therapy 3.1 (2022): 27. [4] Najjar, Mariana K., et al. "Antibody-drug conjugates for the treatment of HER2-positive breast cancer." Genes 13.11 (2022): 2065. [5] Siddiqui, T., Rani, P., Ashraf, T., & Ellahi, A. (2022). Enhertu (Fam-trastuzumab-deruxtecan-nxki)–Revolutionizing treatment paradigm for HER2-Low breast cancer. Annals of Medicine and Surgery, 82. [6] Nahta R, Esteva F J. Herceptin: mechanisms of action and resistance[J]. Cancer letters, 2006, 232(2): 123-138. [7] Kute, Timothy, et al. "Development of Herceptin resistance in breast cancer cells." Cytometry Part A: the journal of the International Society for Analytical Cytology 57.2 (2004): 86-93. [8] Nguyen, Toan D., Brandon M. Bordeau, and Joseph P. Balthasar. "Mechanisms of ADC toxicity and strategies to increase ADC tolerability." Cancers 15.3 (2023): 713. [9] Chowdhury, Ruhe, and Paul Ellis. "Trastuzumab (Herceptin®) and Ado‐Trastuzumab Emtansine (Kadcyla®): treatments for HER2‐positive breast cancer." Handbook of therapeutic antibodies (2014): 2041-2068. [10] Menezes, Bruna, et al. "An agent-based systems pharmacology model of the antibody-drug conjugate kadcyla to predict efficacy of different dosing regimens." The AAPS journal 22 (2020): 1-13. [11] Najjar, Mariana K., et al. "Antibody-drug conjugates for the treatment of HER2-positive breast cancer." Genes 13.11 (2022): 2065.